6-Bromoimidazo[1,2-a]pyrazin-2-amine, 95.0%, 500mg

1-Methoxy-2-propanol, min. 99%, for synthesis, 2.5 L, glass packaging

(2R,5R)-2-Methyl-5-(prop-1-en-2-yl)cyclohexanone, 95.0%, 5g

2-(3-Chloro-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 1g

2-Cyano-5-fluorobenzoic acid, 95.0%, 1g

Lorlatinib, 99.92%, 1g

3-Hydroxybenzotrifluoride>98.0%(GC)250g

4-Methyl-3-oxo-pentanoic acid ethyl ester, 95.0%, 1g

tert-Butyl spiro[indene-1,4'-piperidine]-1'-carboxylate, 95.0%, 1g

1,9-Nonanediol, 95.0%, 1g

3-[methyl(phenyl)amino]propanoic acid hydrochloride, 95%, 250mg

Potassium Hexafluorophosphate>95.0%(T)100g

3-(2,3-Dihydro-1h-indol-1-yl)propan-1-amine, 95%, 1g